US4173626A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sustained release indomethacin
Assignee: Merck and Co Inc
•
Filing: 1978-12-11
•
Granted: 1979-11-06
•
Expires: 1998-12-11
Abstract
Abstract A sustained release indomethacin pharmaceutical product is provided that utilizes a pellet formulation encapsulated in a hard gelatin capsule. A portion of the pellets is uncoated for immediate and rapid release of indomethacin for elevating the plasma level. The remainder of the pellets are coated with a polymer to sustain the plasma level. The uncoated and coated pellets may be mixed with non-medicated pellets as a capsule filler.
Inventors
- 👤 Robert E. Dempski
- 👤 Gunvant N. Mehta
- 👤 Joseph C. Saboe
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:09
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/405; A61K9/00; A61K9/48; A61K9/50; A61K9/5084
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
101 words
A sustained release pharmaceutical formulation in capsule unit dosage form that provides prolonged plasma levels of indomethacin and is clinically effective, containing 25 to 150 mg of 500 to 1500 micron size pellets of indomethacin, in the form of: (A) Uncoated pellets comprising pharmaceutical carriers and 5-50 mg of indomethacin for immediate release of about 35% of the total indomethacin, and rapid elevation of plasma levels; and (B) Coated pellets comprising pharmaceutical carriers and 15-145 mg of indomethacin as a sustaining dose of about 65% of the total indomethacin wherein the coating consists of polyvinyl acetate as a slow dissolving material.
Claim 2
Dependent Claim
101 words
A sustained release pharmaceutical formulation in capsule unit dosage form that provides prolonged plasma levels of indomethacin and is clinically effective, containing 25 to 150 mg of 500 to 1500 micron size pellets of indomethacin, in the form of: (A) Uncoated pellets comprising pharmaceutical carriers and 5-50 mg of indomethacin for immediate release of about 35% of the total indomethacin, and rapid elevation of plasma levels; and (B) Coated pellets comprising pharmaceutical carriers and 15-145 mg of indomethacin as a sustaining dose of about 65% of the total indomethacin wherein the coating consists of polyvinyl acetate as a slow dissolving material.
Claim 3
Dependent Claim
25 words
The pharmaceutical formulation of claim 1, wherein the unit dosage form also includes non-medicated pellets to achieve the correct adjusted fill volume for the capsule.
Claim 4
Dependent Claim
50 words
The pharmaceutical formulation of claim 1, wherein component (A) is pellets comprising 10-35% by weight indomethacin; 20-40% by weight confectioner's sugar; 3-15% by weight of hydroxypropylmethylcellulose; 3-15% by weight corn starch; and 15-25% by weight microcrystalline cellulose; and component (B) is component (A) pellets coated with said slow dissolving material.
References Cited (Backward Citations)
DE694708C
Cited
US2702264A
Cited
US2921883A
Cited
US2928770A
Cited
US3081233A
Cited
US3080294A
Cited
US3247066A
Cited
US3325365A
Cited
NL6502190A
Cited
US3400185A
Cited
US3492397A
Cited
US3835221A
Cited
DE2146174A1
Cited
US4083949A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-11-05 | 1983-05-07 | 1983-11-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-11-05 | 1987-05-07 | 1987-11-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-11-05 | 1991-05-07 | 1991-11-06 | $7700.00 | Window Closed / Lapsed |